"Daudi人Burkitt's淋巴瘤細胞代次低|培養(yǎng)基|送STR圖譜

傳代比例：1:2-1:4(首次傳代建議1:2)

生長特性：懸浮生長

細胞系的選擇需要考慮到細胞系的功能特點、生長速率、鋪板效率、生長條件和生長特征、克隆效率、培養(yǎng)方式等因素，如果您想高產(chǎn)量表達重組蛋白，您可以選擇可以懸浮生長的快速生長細胞系。細胞培養(yǎng)的操作步驟主要包括傳代、換液、凍存和復(fù)蘇。這些步驟確保了細胞能夠在實驗室環(huán)境中長期存活并繼續(xù)增殖。傳代是將細胞從一個容器轉(zhuǎn)移到另一個容器的過程，以擴大細胞數(shù)量；換液是為了清除代謝廢物并補充新鮮培養(yǎng)基；凍存則是為了長期保存細胞，而復(fù)蘇則是重新激活冷凍保存的細胞使其恢復(fù)正常生長。

換液周期：每周2-3次

IHH Cells;背景說明：肝;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：HS5細胞、Jurkat-E6細胞、LPC-H12細胞

SKBr3 Cells;背景說明：這株細胞源自胸水。沒有病毒顆粒。亞顯微結(jié)構(gòu)特征包括微絲和橋粒，肝糖原顆粒，大溶酶體，成束的細胞質(zhì)纖絲。SK-BR-３細胞株過表達HER２/c-erb-２基因產(chǎn)物。;傳代方法：消化３-５分鐘，１：２,３天內(nèi)可長滿;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：Hs-281-T細胞、HFTF細胞、OAW 42細胞

MKN28 Cells;背景說明：詳見相關(guān)文獻介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：TOV112細胞、D324細胞、SKLU1細胞

Daudi人Burkitt's淋巴瘤細胞代次低|培養(yǎng)基|送STR圖譜

背景信息：１９６７年，該細胞系KleinE和KleinG建系，源于一名１６歲患有Burkitt＇s淋巴瘤的黑人男性，beta-２-微球蛋白陰性，表達EBNA,VCA，sIg。該細胞攜帶EB病毒，是一個典型的B淋巴母細胞系，可用于白血病發(fā)病機制的研究。

┈訂┈購(技術(shù)服務(wù))┈熱┈線：1┈3┈6┈4┈1┈9┈3┈0┈7┈9┈1【微信同號】┈Q┈Q：3┈1┈8┈0┈8┈0┈7┈3┈2┈4；

貼壁細胞(adherent cells)：該類細胞的生長必須有可以貼附的支持物表面，細胞依靠自身分泌的或培養(yǎng)基中提供的貼附因子才能在該表面上生長，繁殖；當(dāng)細胞在該表面生長后，一般形成兩種形態(tài)，即成纖維樣細胞性或上皮樣細胞；其生長過程分為游離期、貼壁期、潛伏期、對數(shù)期、平臺期和衰退期。懸浮細胞(suspension cell)：不貼附于生長物，細胞呈圓形，呈單個細胞或者細小細胞團，懸浮細胞生長空間大，傳代方便，能夠大量增殖。

產(chǎn)品包裝：復(fù)蘇發(fā)貨：T25培養(yǎng)瓶(一瓶)或凍存發(fā)貨：1ml凍存管(兩支)

來源說明：細胞主要來源ATCC、ECACC、DSMZ、RIKEN等細胞庫

Daudi人Burkitt's淋巴瘤細胞代次低|培養(yǎng)基|送STR圖譜

物種來源：人源、鼠源等其它物種來源

SKM1 Cells;背景說明：詳見相關(guān)文獻介紹;傳代方法：１：２傳代；;生長特性：貼壁生長;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：QBC-939細胞、KBM-5細胞、NCIH647細胞

Line 697 Cells;背景說明：B淋巴細胞白血??；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：懸浮;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：HUT 226細胞、L-cells細胞、HeLa-S3細胞

HES [Human embryonic skin fibroblast] Cells;背景說明：皮膚；成纖維 Cells;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：QSG7701細胞、HOP62細胞、THPI細胞

UWB1.289+BRCA1 Cells;背景說明：詳見相關(guān)文獻介紹;傳代方法：１：２傳代;生長特性：貼壁生長　;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：Capan 1細胞、MDA-MB-435細胞、SUM149細胞

┈訂┈購(技術(shù)服務(wù))┈熱┈線：1┈3┈6┈4┈1┈9┈3┈0┈7┈9┈1【微信同號】┈Q┈Q：3┈1┈8┈0┈8┈0┈7┈3┈2┈4；

形態(tài)特性：淋巴母細胞樣

細胞培養(yǎng)無菌操作步驟和注意事項：１.打開無菌工作臺及凈化室的紫外燈，消毒半小時以上。２.進入凈化室前先關(guān)閉紫外燈，打開超凈臺風(fēng)機，等待３０min以上，以排盡臭氧。３.穿HAO隔離衣，戴HAO口罩，帽子。４.風(fēng)淋２分鐘。５.０.１%水泡手，擦干。６.點燃酒精燈;超凈臺內(nèi)應(yīng)避免放入過多的物品;使用的吸管，滴管，試管，培養(yǎng)瓶等均事先滅菌。７.打開各類瓶蓋前先過火，以固定灰塵;打開的瓶口、試管口過火焰，鑷子使用前應(yīng)經(jīng)火焰燒灼。８.水平式風(fēng)機的超凈臺，應(yīng)使瓶口斜置，應(yīng)盡量避免瓶口敞開直立。９.同一根吸管或滴管不應(yīng)連續(xù)用于幾個不同的細胞系；吸取培養(yǎng)基的吸管應(yīng)離開培養(yǎng)瓶或試管口０.５cm，避免伸入培養(yǎng)瓶口或試管口；以防止細胞系的互相混雜污染。１０.漏在培養(yǎng)瓶上或臺上的體，立即用酒精棉球擦凈。１１.操作完畢后恢復(fù)工作臺面。

UPCI-SCC-90 Cells;背景說明：舌鱗癌細胞；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：OCI AML4細胞、SU-DHL-10細胞、HCCC-9810細胞

SW-13 Cells;背景說明：詳見相關(guān)文獻介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：B35細胞、RH35細胞、MCF-7B細胞

Rin-M-5F Cells;背景說明：胰島β細胞瘤；雄性；NEDH;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：HuP-T3細胞、HCC-1806細胞、EOC-20細胞

TR-146 Cells;背景說明：食管鱗癌;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：MDA-231細胞、University of Michigan-Urothelial Carcinoma-3細胞、CHO細胞

Colon38 Cells;背景說明：詳見相關(guān)文獻介紹;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：上皮細胞樣;相關(guān)產(chǎn)品有：H125細胞、RC13細胞、JF305細胞

Hepatoma-22 Cells;背景說明：１９５２年，前蘇聯(lián)醫(yī)學(xué)科學(xué)院腫瘤研究所以C３HA小鼠誘發(fā)的H２２肝癌實體瘤的瘤細胞懸液，昆明種小鼠皮下移植后，轉(zhuǎn)腹水瘤。經(jīng)檢測，該瘤株在Km小鼠、６１５小鼠、C５７BL/６小鼠、BALB/C小鼠體內(nèi)可以形成實體瘤和腹水瘤。;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：懸浮;形態(tài)特性：淋巴母細胞;相關(guān)產(chǎn)品有：NCI.H522細胞、Colo320細胞、B-104細胞

KRCY Cells;背景說明：腎透明細胞癌；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：MDCK-II細胞、Ly18細胞、MDA231-LM2細胞

PNT-1A Cells;背景說明：詳見相關(guān)文獻介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：SV40 MES 13細胞、A9 (Hamprecht)細胞、GMK,BSC-1細胞

HEI193 Cells;背景說明：神經(jīng)鞘瘤；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：DLD1細胞、138MG細胞、UMNSAH/DF-1細胞

Centre Antoine Lacassagne-12T Cells;背景說明：詳見相關(guān)文獻介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：MDA MB 134VI細胞、HOS細胞、Bronchial Epithelium transformed with Ad12-SV40 2B細胞

MDA MB 453 Cells;背景說明：該細胞系由CailleauR在１９７６年從一名４８歲的患有轉(zhuǎn)移性乳腺癌的白人女性的心包滲出液中分離建立的。該細胞表達FGF的受體。;傳代方法：１：２-１：４傳代；２-３天換液１次;生長特性：貼壁生長;形態(tài)特性：上皮樣；多角形;相關(guān)產(chǎn)品有：M-G63細胞、T47D:A細胞、C32-mel細胞

H-1436 Cells;背景說明：詳見相關(guān)文獻介紹;傳代方法：隨細胞的密度而增加;生長特性：懸浮生長;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：PNT1/A細胞、SUM-52-PE細胞、Hca-F細胞

CCC-ESF-1 Cells;背景說明：胚胎；皮膚；成纖維 Cells;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：H1781細胞、Namalwa細胞、MB231細胞

CAKI 1 Cells;背景說明：該細胞超微結(jié)構(gòu)中包含許多微絨毛、少許微絲、許多小線粒體、發(fā)達的高爾基休和內(nèi)質(zhì)網(wǎng)、許多脂滴和多層體、次級溶酶體，沒有發(fā)現(xiàn)病毒顆粒。;傳代方法：１：２-１：４傳代；每周換液２-３次。;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：OCI Ly10細胞、MILE SVEN1細胞、RC-4B/C細胞

NIH:OVCAR-10 Cells;背景說明：卵巢癌；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：RPTEC TERT1細胞、HONE-1細胞、MDA MB 175 VII細胞

RIN m5F Cells;背景說明：胰島β細胞瘤；雄性；NEDH;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：H-2141細胞、ROS-17/2.8細胞、SF 295細胞

Hs746T Cells;背景說明：詳見相關(guān)文獻介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：CEMC1細胞、TE-6細胞、U-87細胞

Abcam HCT 116 GADD45B KO Cells(提供STR鑒定圖譜)

AG06842 Cells(提供STR鑒定圖譜)

BayGenomics ES cell line CSI670 Cells(提供STR鑒定圖譜)

BayGenomics ES cell line STA072 Cells(提供STR鑒定圖譜)

BIONi010-C-24 Cells(提供STR鑒定圖譜)

CIN-612 3E Cells(提供STR鑒定圖譜)

DA03253 Cells(提供STR鑒定圖譜)

ESC 98B27 Cells(提供STR鑒定圖譜)

GM06888 Cells(提供STR鑒定圖譜)

DHL-16 Cells;背景說明：詳見相關(guān)文獻介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：MyLa2059細胞、NS1-Ag4細胞、ARO81-1細胞

Daudi人Burkitt's淋巴瘤細胞代次低|培養(yǎng)基|送STR圖譜

MEC1 Cells;背景說明：粘液表皮樣癌;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：J 111細胞、Rat Chondrosarcoma Swarm細胞、SK Col 1細胞

H-1648 Cells;背景說明：詳見相關(guān)文獻介紹;傳代方法：１：３-１：６傳代;生長特性：貼壁生長;形態(tài)特性：上皮細胞;相關(guān)產(chǎn)品有：OVCAR-3細胞、MLMEC細胞、CPA47細胞

OCM1 Cells;背景說明：葡萄膜黑色素瘤；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：CTV-1細胞、hTERTHME1細胞、CL-11細胞

WiDr/S Cells;背景說明：結(jié)腸癌；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：WERI-Rb1細胞、MDCK (NBL-2)細胞、Hs-343-T細胞

WB F344 Cells;背景說明：詳見相關(guān)文獻介紹;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：T-HSC細胞、LS-174T細胞、RPMI8226/S細胞

Alpha-TSH Cells(提供STR鑒定圖譜)

HT-115 Cells;背景說明：結(jié)腸癌;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：32D.3細胞、HSMC細胞、A-172 MG細胞

R.K.13 Cells;背景說明：詳見相關(guān)文獻介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：MDA-MB-134-VI細胞、Microbiological Associates-104細胞、OCI AML5細胞

H1395 Cells;背景說明：詳見相關(guān)文獻介紹;傳代方法：１：２傳代；５-６天傳代一次。;生長特性：貼壁生長;形態(tài)特性：上皮樣；多角形;相關(guān)產(chǎn)品有：MIO-M1細胞、Hs840_T細胞、Caco2BBe細胞

Balb/3T3-4-Cl31 Cells;背景說明：胚胎；成纖維；自發(fā)永生；雄性；BALB/c;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：PL-5細胞、Tb1.Lu細胞、CHG5細胞

AM Cells;背景說明：詳見相關(guān)文獻介紹;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：上皮細胞;相關(guān)產(chǎn)品有：HFLS-RA細胞、GLC-15細胞、HO1N1細胞

NCIADRRES Cells;背景說明：詳見相關(guān)文獻介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：RWPE-1細胞、CEL細胞、Mesothelial cells transfected with pRSV-T 5A細胞

VM-CUB-I Cells;背景說明：詳見相關(guān)文獻介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：SHIN-3細胞、HFL 1細胞、HOS(TE85)細胞

COV504 Cells;背景說明：詳見相關(guān)文獻介紹;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：上皮細胞;相關(guān)產(chǎn)品有：H341細胞、Rh30細胞、Hs 27細胞

HaEpi Cells(提供STR鑒定圖譜)

HAP1 RPS6KB1 (-) Cells(提供STR鑒定圖譜)

INS-1 Cells;背景說明：該細胞源自X射線照射的移植胰島瘤的大鼠，胰島素陽性，可合成胰島素原I和II，可用于beta細胞功能研究。;傳代方法：１：３—１：６傳代，每周換液２—３次;生長特性：貼壁生長;形態(tài)特性：不規(guī)則，多角;相關(guān)產(chǎn)品有：BALL1細胞、22Rv1細胞、COLO 206細胞

Hs 604.T Cells;背景說明：詳見相關(guān)文獻介紹;傳代方法：１：２傳代；每周換液２-３次。;生長特性：貼壁生長;形態(tài)特性：成纖維細胞;相關(guān)產(chǎn)品有：H2073細胞、L(TK-)細胞、U266-B1細胞

RPMI7951 Cells;背景說明：詳見相關(guān)文獻介紹;傳代方法：１：２-１：４傳代，２天換液１次。;生長特性：貼壁生長;形態(tài)特性：上皮細胞;相關(guān)產(chǎn)品有：SK-N-BE(2)-C細胞、HT144細胞、TGW-nu細胞

COLO-357 Cells;背景說明：胰腺癌；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：SNU449細胞、S91細胞、MM1.S細胞

L-02 Cells;背景說明：詳見相關(guān)文獻介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：H4IIE細胞、H-2330細胞、ECC 12細胞

Caco-2BBe Cells;背景說明：詳見相關(guān)文獻介紹;傳代方法：１：６—１：１０傳代，每周換液２次;生長特性：貼壁生長;形態(tài)特性：上皮細胞;相關(guān)產(chǎn)品有：SW 954細胞、SCC-9細胞、NCI-H2141細胞

H-526 Cells;背景說明：詳見相關(guān)文獻介紹;傳代方法：每周換液２-３次。;生長特性：懸浮生長 ;形態(tài)特性：上皮細胞;相關(guān)產(chǎn)品有：HMEC-1細胞、GM05384細胞、Mono-Mac-1細胞

MOLT 4 Cells;背景說明：MOLT-４與MOLT-３來源于一名１９歲的男性急性淋巴細胞性白血病的復(fù)發(fā)患者，該患者前期接受過多種藥物聯(lián)合化療。MOLT-４細胞系為T淋巴細胞起源，p５３基因的第２４８位密碼子有一個G→A突變，不表達p５３，不表達免疫球蛋白或EB病毒；可產(chǎn)生高水平的末端脫氧核糖轉(zhuǎn)移酶；表達CD１(４９%),CD２(３５%),CD３A(２６%)B(３３%)C(３４%),CD４(５５%),CD５(７２%),CD６(２２%),CD７(７７%)。;傳代方法：１：２傳代;生長特性：懸浮生長;形態(tài)特性：淋巴母細胞樣；圓形;相關(guān)產(chǎn)品有：NCI-H676B細胞、NBLAN5T細胞、TMK-1細胞

HyCyte A-549 KO-hSIRT1 Cells(提供STR鑒定圖譜)

LB 84-1 Cells(提供STR鑒定圖譜)

MVX-1 Cells(提供STR鑒定圖譜)

OU-AML-6 Cells(提供STR鑒定圖譜)

RPMI-6410 Cells(提供STR鑒定圖譜)

Ubigene HEK293 PDHA1 KO Cells(提供STR鑒定圖譜)

WG3298 Cells(提供STR鑒定圖譜)

HCT116-SLC46A1-KO-c5 Cells(提供STR鑒定圖譜)

TT Cells;背景說明：TT細胞由LeongSS等，自一位７７歲白人女性甲狀腺髓樣癌患者的穿刺活檢樣本中建立。TT細胞持續(xù)產(chǎn)生高水平的降血素和CEA。更換培養(yǎng)基后２４h和７２h，在培養(yǎng)基中檢測到的免疫活性的降血素濃度分別為３９００pg/１０６個細胞和７７００pg/１０６個細胞。７２小時后CEA積累濃度超過２７ng/１０６個細胞；該細胞最初是在RPMI１６４０培養(yǎng)液中培養(yǎng)，可產(chǎn)生神經(jīng)肽，但還不知道在F１２培養(yǎng)液中培養(yǎng)是否會產(chǎn)生。;傳代方法：１：３-１：４傳代，每周換液２次。;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：IEC 6細胞、no.11細胞、GM04154B細胞

HBZY1 Cells;背景說明：詳見相關(guān)文獻介紹;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：上皮細胞樣;相關(guān)產(chǎn)品有：VeroE6細胞、Mac-1細胞、LS 174T細胞

PCI-4M Cells;背景說明：喉鱗癌；淋巴結(jié)轉(zhuǎn)移；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：hTERT RPE1細胞、52PE細胞、WM451Lu細胞

KU.812 Cells;背景說明：詳見相關(guān)文獻介紹;傳代方法：１：２傳代。３天內(nèi)可長滿;生長特性：懸浮生長;形態(tài)特性：骨髓母細胞;相關(guān)產(chǎn)品有：J-774A.1細胞、Hi-five細胞、HEK-293-H細胞

U 138 MG Cells;背景說明：星形細胞瘤；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：A375-MEL細胞、R-1059-D細胞、32D-Cl3細胞

U 138 MG Cells;背景說明：星形細胞瘤；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：A375-MEL細胞、R-1059-D細胞、32D-Cl3細胞

HLFa Cells;背景說明：詳見相關(guān)文獻介紹;傳代方法：１：２-１：４傳代；每周換液２次。;生長特性：貼壁生長;形態(tài)特性：成纖維細胞;相關(guān)產(chǎn)品有：H1563細胞、SNU-398細胞、H2196細胞

NCI-H676B Cells;背景說明：詳見相關(guān)文獻介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：J82細胞、CPAE細胞、A-427細胞

H-1666 Cells;背景說明：詳見相關(guān)文獻介紹;傳代方法：１：２-１：４傳代；每周換液２次。;生長特性：貼壁生長，松散;形態(tài)特性：上皮細胞;相關(guān)產(chǎn)品有：OCI-AML-2細胞、BE(2)M-17細胞、HCC1428細胞

COLO 394 Cells;背景說明：詳見相關(guān)文獻介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：HRPEpiC細胞、NPC-TW-039細胞、MHCC 97-L細胞

U-138 MG Cells;背景說明：星形細胞瘤；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：NCIH196細胞、A549/DDP細胞、VMRCRCZ細胞

U118MG Cells;背景說明：注意： 據(jù)報道來自不同個體的膠質(zhì)母細胞瘤細胞株U-１１８ MG (HTB-１５) 和 U-１３８ MG (HTB-１６)有著一致的VNTR和相近的STR模式。 U-１１８ MG 和 U-１３８ MG細胞遺傳學(xué)上很相似并有至少六個衍生標記染色體。 這是１９６６年至１９６９年間J. Ponten和同事從惡性神經(jīng)膠質(zhì)瘤中構(gòu)建的細胞株中的一株(其它包括ATCC HTB-１４和 ATCC HTB-１６ and ATCC HTB-１７)。 １９８７年用BM-Cycline培養(yǎng)６周去除了支原體污染。 ;傳代方法： 消化３-５分鐘。１：２傳代。３天內(nèi)可長滿。;生長特性：貼壁生長;形態(tài)特性：混合型;相關(guān)產(chǎn)品有：NCI-H2141細胞、TCCSUP細胞、SNU-878細胞

JS1 Cells;背景說明：肝星形 Cells;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：786-O RCC細胞、GM07404A細胞、CHP-126細胞

Daoy Cells;背景說明：詳見相關(guān)文獻介紹;傳代方法：１：４-１：６傳代；每周換液２-３次。;生長特性：貼壁生長;形態(tài)特性：多邊形;相關(guān)產(chǎn)品有：KMB-17細胞、UMRC-2細胞、Rat-2細胞

HRA 19 Cells;背景說明：詳見相關(guān)文獻介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：Rat Lung Epithelial-6-T-antigen Negative細胞、NCI-H2444細胞、L02細胞

TBE-1 [Scophthalmus] Cells(提供STR鑒定圖譜)

Ramos.G6.C10 Cells;背景說明：詳見相關(guān)文獻介紹;傳代方法： 維持細胞濃度在２×１０５/ml-１×１０６/ml；根據(jù)細胞濃度每２-３天補液１次。;生長特性：懸浮生長 ;形態(tài)特性：淋巴母細胞樣;相關(guān)產(chǎn)品有：MC-3T3細胞、ONS-76細胞、HUC細胞

HCC44 Cells;背景說明：詳見相關(guān)文獻介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：NCIH358細胞、SF295細胞、ME1細胞

H2286 Cells;背景說明：詳見相關(guān)文獻介紹;傳代方法：１：２-１：４傳代；每周換液２次。;生長特性：貼壁生長;形態(tài)特性：橢圓形;相關(guān)產(chǎn)品有：KU-812F細胞、MUVEC細胞、SuDHL 8細胞

A375-S2 Cells;背景說明：詳見相關(guān)文獻介紹;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：Roswell Park Memorial Institute 7666細胞、SU-DHL-16細胞、C8166細胞

LS-180 Cells;背景說明：詳見相關(guān)文獻介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：COLO678細胞、ABC1細胞、K1735細胞

DMS-114 Cells;背景說明：詳見相關(guān)文獻介紹;傳代方法：１：２-１：４傳代；每周換液２次。;生長特性：貼壁生長;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：MDAMB-231細胞、253J細胞、293AD細胞

Daudi人Burkitt's淋巴瘤細胞代次低|培養(yǎng)基|送STR圖譜

H2110 Cells;背景說明：詳見相關(guān)文獻介紹;傳代方法：１：３-１：６傳代，每周換液２-３次;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：上皮細胞;相關(guān)產(chǎn)品有：COV504細胞、HEK-AD 293細胞、CCD18Co細胞

SUM-159PT Cells;背景說明：乳腺癌；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：Hs683細胞、OCI-LY-3細胞、LC2/Ad細胞

KCL-22 Cells;背景說明：詳見相關(guān)文獻介紹;傳代方法：１：２傳代;生長特性：懸浮;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：Central Adrenergic TH-expressing a細胞、MKN28細胞、SaOS細胞

PC-3M-IE8 Cells;背景說明：前列腺癌；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：MDA-MB-231-GFP細胞、Balb/c3T3細胞、H1930細胞

CMT-167 Cells;背景說明：肺腺癌；雌性；C５７BL/ICRF-a(t);傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：SCLC21H細胞、2V6.11細胞、PIGI細胞

Shadyside Hospital Pittsburgh-77 Cells;背景說明：詳見相關(guān)文獻介紹;傳代方法：３-４天換液１次。;生長特性：懸浮生長，少量貼壁;形態(tài)特性：上皮細胞;相關(guān)產(chǎn)品有：H9c2 (2-1)細胞、ES-2細胞、KYSE520細胞

NCIH2073 Cells;背景說明：詳見相關(guān)文獻介紹;傳代方法：１：３-１：６傳代 ;生長特性：貼壁生長;形態(tài)特性：上皮細胞;相關(guān)產(chǎn)品有：DSL6A/C1細胞、OVCAR5細胞、SUPM2細胞

KRC-Y Cells;背景說明：腎透明細胞癌；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：RBL-2H3細胞、MOLP-2細胞、Transformed Human Liver Epithelial-2細胞

BayGenomics ES cell line NPX312 Cells(提供STR鑒定圖譜)

BayGenomics ES cell line XC512 Cells(提供STR鑒定圖譜)

CPTC-GPI-1 Cells(提供STR鑒定圖譜)

mBMS-B18 Cells(提供STR鑒定圖譜)

SC17.79 Cells(提供STR鑒定圖譜)

LK24 Cells(提供STR鑒定圖譜)

" "PubMed=4321974

Maurer B.A., Imamura T., Wilbert S.M.

Incidence of EB virus-containing cells in primary and secondary clones of several Burkitt lymphoma cell lines.

Cancer Res. 30:2870-2875(1970)

PubMed=4122458; DOI=10.1002/ijc.2910100108

Klein G., Dombos L., Gothoskar B.

Sensitivity of Epstein-Barr virus (EBV) producer and non-producer human lymphoblastoid cell lines to superinfection with EB-virus.

Int. J. Cancer 10:44-57(1972)

PubMed=5021706; PMCID=PMC1407864

van Furth R., Gorter H., Nadkarni J.S., Nadkarni J.J., Klein E., Clifford P.

Synthesis of immunoglobulins by biopsied tissues and cell lines from Burkitt's lymphoma.

Immunology 22:847-857(1972)

PubMed=4364259; DOI=10.1002/ijc.2910110210

Klein G., Dombos L.

Relationship between the sensitivity of EBV-carrying lymphoblastoid lines to superinfection and the inducibility of the resident viral genome.

Int. J. Cancer 11:327-337(1973)

PubMed=170370; DOI=10.1099/0022-1317-28-2-207

Adams A., Strander H., Cantell K.

Sensitivity of the Epstein-Barr virus transformed human lymphoid cell lines to interferon.

J. Gen. Virol. 28:207-217(1975)

PubMed=216485

Higgins N.P., Strauss B.S.

Differences in the ability of human lymphoblastoid lines to exclude bromodeoxyuridine and in their sensitivity to methyl methanesulfonate and to incorporated [3H]thymidine.

Cancer Res. 39:312-320(1979)

PubMed=7316467; DOI=10.1111/j.1469-1809.1980.tb00953.x

Povey S., Jeremiah S., Arthur E., Steel M., Klein G.

Differences in genetic stability between human cell lines from patients with and without lymphoreticular malignancy.

Ann. Hum. Genet. 44:119-133(1980)

PubMed=6935474; DOI=10.1093/jnci/66.2.239

Wright W.C., Daniels W.P., Fogh J.

Distinction of seventy-one cultured human tumor cell lines by polymorphic enzyme analysis.

J. Natl. Cancer Inst. 66:239-247(1981)

PubMed=6286763; DOI=10.4049/jimmunol.129.3.1336

Benjamin D., Magrath I.T., Maguire R.T., Janus C., Todd-Kulikowsk H.D., Parsons R.G.

Immunoglobulin secretion by cell lines derived from African and American undifferentiated lymphomas of Burkitt's and non-Burkitt's type.

J. Immunol. 129:1336-1342(1982)

PubMed=6806672; DOI=10.1038/298474a0

Lenoir G.M., Preud'homme J.-L., Bernheim A., Berger R.

Correlation between immunoglobulin light chain expression and variant translocation in Burkitt's lymphoma.

Nature 298:474-476(1982)

PubMed=6954533; DOI=10.1073/pnas.79.7.2194; PMCID=PMC346157

Westin E.H., Gallo R.C., Arya S.K., Eva A., Souza L.M., Baluda M.A., Aaronson S.A., Wong-Staal F.

Differential expression of the amv gene in human hematopoietic cells.

Proc. Natl. Acad. Sci. U.S.A. 79:2194-2198(1982)

PubMed=6186604; DOI=10.1007/BF00364753

de Preval C., Mach B.

The absence of beta 2-microglobulin in Daudi cells: active gene but inactive messenger RNA.

Immunogenetics 17:133-140(1983)

PubMed=11894933; DOI=10.1002/j.1460-2075.1983.tb01412.x; PMCID=PMC555120

Rosa F.M., Berissi H., Weissenbach J., Maroteaux L., Fellous M., Revel M.

The beta2-microglobulin mRNA in human Daudi cells has a mutated initiation codon but is still inducible by interferon.

EMBO J. 2:239-243(1983)

PubMed=6200433; DOI=10.1007/BF00364762

Brodsky F.M.

A matrix approach to human class II histocompatibility antigens: reactions of four monoclonal antibodies with the products of nine haplotypes.

Immunogenetics 19:179-194(1984)

PubMed=6231253; DOI=10.1002/ijc.2910330407

Ehlin-Henriksson B., Klein G.

Distinction between Burkitt lymphoma subgroups by monoclonal antibodies: relationships between antigen expression and type of chromosomal translocation.

Int. J. Cancer 33:459-463(1984)

PubMed=6500159; DOI=10.1159/000163283

Gershwin M.E., Lentz D., Owens R.B.

Relationship between karyotype of tissue culture lines and tumorigenicity in nude mice.

Exp. Cell Biol. 52:361-370(1984)

PubMed=6547209; DOI=10.1038/309592a0

Rabbitts T.H., Forster A., Hamlyn P.H., Baer R.

Effect of somatic mutation within translocated c-myc genes in Burkitt's lymphoma.

Nature 309:592-597(1984)

PubMed=6582512; DOI=10.1073/pnas.81.2.568; PMCID=PMC344720

Mattes M.J., Cordon-Cardo C., Lewis J.L. Jr., Old L.J., Lloyd K.O.

Cell surface antigens of human ovarian and endometrial carcinoma defined by mouse monoclonal antibodies.

Proc. Natl. Acad. Sci. U.S.A. 81:568-572(1984)

PubMed=6592381; DOI=10.1093/jnci/73.4.841

Favrot M.-C., Philip I., Philip T., Portoukalian J., Dore J.-F., Lenoir G.M.

Distinct reactivity of Burkitt's lymphoma cell lines with eight monoclonal antibodies correlated with the ethnic origin.

J. Natl. Cancer Inst. 73:841-847(1984)

PubMed=2985879; DOI=10.1016/0145-2126(85)90084-0

Drexler H.G., Gaedicke G., Minowada J.

Isoenzyme studies in human leukemia-lymphoma cell lines -- 1 carboxylic esterase.

Leuk. Res. 9:209-229(1985)

PubMed=2998993

Steel C.M., Morten J.E.N., Foster E.

The cytogenetics of human B lymphoid malignancy: studies in Burkitt's lymphoma and Epstein-Barr virus-transformed lymphoblastoid cell lines.

IARC Sci. Publ. 60:265-292(1985)

PubMed=3159941; DOI=10.1016/0145-2126(85)90134-1

Drexler H.G., Gaedicke G., Minowada J.

Isoenzyme studies in human leukemia-lymphoma cell lines -- III Beta-hexosaminidase (E.C. 3.2.1.30).

Leuk. Res. 9:549-559(1985)

PubMed=3874327; DOI=10.1016/0145-2126(85)90133-x

Drexler H.G., Gaedicke G., Minowada J.

Isoenzyme studies in human leukemia-lymphoma cells lines -- II. Acid phosphatase.

Leuk. Res. 9:537-548(1985)

PubMed=3905596

Favrot M.-C., Philip I., Philip T., Cabrillat H., Pinatel C., Dore J.-F., Lenoir G.M.

Immunophenotypic classification of 28 Burkitt cell lines with monoclonal antibodies and reagent selection for bone-marrow purging.

IARC Sci. Publ. 60:447-452(1985)

PubMed=3080238

Sieverts H., Alabaster O., Goldschmidts W., Magrath I.T.

Expression of surface antigens during the cell cycle in different growth phases of American and African Burkitt's lymphoma cell lines.

Cancer Res. 46:1182-1188(1986)

PubMed=3100061; DOI=10.1016/0008-8749(86)90099-7

Benjamin D., Bazar L.S., Wallace B., Jacobson R.J.

Heterogeneity of B-cell growth factor receptor reactivity in healthy donors and in patients with chronic lymphatic leukemia: relationship to B-cell-derived lymphokines.

Cell. Immunol. 103:394-408(1986)

PubMed=3518877; DOI=10.3109/07357908609038260

Fogh J.

Human tumor lines for cancer research.

Cancer Invest. 4:157-184(1986)

PubMed=3785169; DOI=10.1128/mcb.6.5.1374-1378.1986; PMCID=PMC367660

Dron M., Modjtahedi N., Brison O., Tovey M.G.

Interferon modulation of c-myc expression in cloned Daudi cells: relationship to the phenotype of interferon resistance.

Mol. Cell. Biol. 6:1374-1378(1986)

PubMed=3026973; DOI=10.1002/ijc.2910390215

Ehlin-Henriksson B., Manneborg-Sandlund A., Klein G.

Expression of B-cell-specific markers in different Burkitt lymphoma subgroups.

Int. J. Cancer 39:211-218(1987)

PubMed=3034807; DOI=10.1002/ijc.2910390622

Ohno H., Fukuhara S., Takahashi R., Mihara K.-i., Sugiyama T., Doi S., Uchino H., Toyoshima K.

c-yes and bcl-2 genes located on 18q21.3 in a follicular lymphoma cell line carrying a t(14;18) chromosomal translocation.

Int. J. Cancer 39:785-788(1987)

PubMed=3116544; DOI=10.1073/pnas.84.19.6835; PMCID=PMC299179

Haluska F.G., Tsujimoto Y., Croce C.M.

The t(8;14) chromosome translocation of the Burkitt lymphoma cell line Daudi occurred during immunoglobulin gene rearrangement and involved the heavy chain diversity region.

Proc. Natl. Acad. Sci. U.S.A. 84:6835-6839(1987)

PubMed=2470097; DOI=10.1073/pnas.86.9.3257; PMCID=PMC287109

Shtivelman E., Henglein B., Groitl P., Lipp M., Bishop J.M.

Identification of a human transcription unit affected by the variant chromosomal translocations 2;8 and 8;22 of Burkitt lymphoma.

Proc. Natl. Acad. Sci. U.S.A. 86:3257-3260(1989)

PubMed=2140233; DOI=10.1111/j.1440-1827.1990.tb01549.x

Nakano A., Harada T., Morikawa S., Kato Y.

Expression of leukocyte common antigen (CD45) on various human leukemia/lymphoma cell lines.

Acta Pathol. Jpn. 40:107-115(1990)

PubMed=2052620; DOI=10.1073/pnas.88.12.5413; PMCID=PMC51883

Gaidano G., Ballerini P., Gong J.Z., Inghirami G., Neri A., Newcomb E.W., Magrath I.T., Knowles D.M., Dalla-Favera R.

p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia.

Proc. Natl. Acad. Sci. U.S.A. 88:5413-5417(1991)

CLPUB00447

Mulivor R.A., Suchy S.F.

1992/1993 catalog of cell lines. NIGMS human genetic mutant cell repository. 16th edition. October 1992.

(In misc. document) Institute for Medical Research (Camden, N.J.) NIH 92-2011; pp.1-918; National Institutes of Health; Bethesda; USA (1992)

PubMed=1325212; DOI=10.1182/blood.V80.5.1289.1289

Benjamin D., Knobloch T.J., Dayton M.A.

Human B-cell interleukin-10: B-cell lines derived from patients with acquired immunodeficiency syndrome and Burkitt's lymphoma constitutively secrete large quantities of interleukin-10.

Blood 80:1289-1298(1992)

PubMed=8301159; DOI=10.1089/jir.1993.13.377

Dron M., Tovey M.G.

Interferon-resistant Daudi cells are deficient in interferon-alpha-induced ISGF3 alpha activation, but remain sensitive to the interferon-alpha-induced increase in ISGF3 gamma content.

J. Interferon Res. 13:377-383(1993)

PubMed=8515068; DOI=10.4049/jimmunol.150.12.5418

Jain V.K., Judde J.-G., Max E.E., Magrath I.T.

Variable IgH chain enhancer activity in Burkitt's lymphomas suggests an additional, direct mechanism of c-myc deregulation.

J. Immunol. 150:5418-5428(1993)

PubMed=8176200; DOI=10.4049/jimmunol.152.10.4749

Benjamin D., Sharma V., Knobloch T.J., Armitage R.J., Dayton M.A., Goodwin R.G.

B cell IL-7. Human B cell lines constitutively secrete IL-7 and express IL-7 receptors.

J. Immunol. 152:4749-4757(1994)

PubMed=8197130; DOI=10.1073/pnas.91.11.4751; PMCID=PMC43866

Bicknell D.C., Rowan A.J., Bodmer W.F.

Beta 2-microglobulin gene mutations: a study of established colorectal cell lines and fresh tumors.

Proc. Natl. Acad. Sci. U.S.A. 91:4751-4755(1994)

PubMed=7849311; DOI=10.1182/blood.V85.4.893.bloodjournal854893

Stranks G., Height S.E., Mitchell P., Jadayel D.M., Yuille M.A.R., De Lord C.F.M., Clutterbuck R.D., Treleaven J.G., Powles R.L., Nacheva E., Oscier D.G., Karpas A., Lenoir G.M., Smith S.D., Millar J.L., Catovsky D., Dyer M.J.S.

Deletions and rearrangement of CDKN2 in lymphoid malignancy.

Blood 85:893-901(1995)

PubMed=8558913

Morita S., Tsuchiya S., Fujie H., Itano M., Ohashi Y., Minegishi M., Imaizumi M., Endo M., Takano N., Konno T.

Cell surface c-kit receptors in human leukemia cell lines and pediatric leukemia: selective preservation of c-kit expression on megakaryoblastic cell lines during adaptation to in vitro culture.

Leukemia 10:102-105(1996)

PubMed=8558920

Dirks W.G., Zaborski M., Jager K., Challier C., Shiota M., Quentmeier H., Drexler H.G.

The (2;5)(p23;q35) translocation in cell lines derived from malignant lymphomas: absence of t(2;5) in Hodgkin-analogous cell lines.

Leukemia 10:142-149(1996)

PubMed=8568269; DOI=10.4049/jimmunol.156.4.1626

Benjamin D., Sharma V., Kubin M., Klein J.L., Sartori A., Holliday J., Trinchieri G.

IL-12 expression in AIDS-related lymphoma B cell lines.

J. Immunol. 156:1626-1637(1996)

PubMed=8847894

Tani A., Tatsumi E., Nakamura F., Kumagai S., Kosaka Y., Sano K., Nakamura H., Amakawa R., Ohno H.

Sensitivity to dexamethasone and absence of bcl-2 protein in Burkitt's lymphoma cell line (Black93) derived from a patient with acute tumor lysis syndrome: comparative study with other BL and non-BL lines.

Leukemia 10:1592-1603(1996)

PubMed=9192833

Cherney B.W., Bhatia K.G., Sgadari C., Gutierrez M.I., Mostowski H.S., Pike S.E., Gupta G., Magrath I.T., Tosato G.

Role of the p53 tumor suppressor gene in the tumorigenicity of Burkitt's lymphoma cells.

Cancer Res. 57:2508-2515(1997)

PubMed=9473234; DOI=10.1182/blood.V91.5.1680

Klangby U., Okan I., Magnusson K.P., Wendland M., Lind P., Wiman K.G.

p16/INK4a and p15/INK4b gene methylation and absence of p16/INK4a mRNA and protein expression in Burkitt's lymphoma.

Blood 91:1680-1687(1998)

PubMed=9510473; DOI=10.1111/j.1349-7006.1998.tb00476.x; PMCID=PMC5921588

Hosoya N., Hangaishi A., Ogawa S., Miyagawa K., Mitani K., Yazaki Y., Hirai H.

Frameshift mutations of the hMSH6 gene in human leukemia cell lines.

Jpn. J. Cancer Res. 89:33-39(1998)

PubMed=9685479; DOI=10.1093/nar/26.16.3651; PMCID=PMC147775

Hultdin M., Gronlund E., Norrback K.-F., Eriksson-Lindstrom E., Just T., Roos G.

Telomere analysis by fluorescence in situ hybridization and flow cytometry.

Nucleic Acids Res. 26:3651-3656(1998)

PubMed=9737686; DOI=10.1038/sj.leu.2401112

Zhang W.-J., Ohnishi K., Shigeno K., Fujisawa S., Naito K., Nakamura S., Takeshita K., Takeshita A., Ohno R.

The induction of apoptosis and cell cycle arrest by arsenic trioxide in lymphoid neoplasms.

Leukemia 12:1383-1391(1998)

PubMed=9738977; DOI=10.1111/j.1349-7006.1998.tb03275.x; PMCID=PMC5921886

Takizawa J., Suzuki R., Kuroda H., Utsunomiya A., Kagami Y., Joh T., Aizawa Y., Ueda R., Seto M.

Expression of the TCL1 gene at 14q32 in B-cell malignancies but not in adult T-cell leukemia.

Jpn. J. Cancer Res. 89:712-718(1998)

PubMed=9973220

Gutierrez M.I., Cherney B.W., Hussain A., Mostowski H.S., Tosato G., Magrath I.T., Bhatia K.G.

Bax is frequently compromised in Burkitt's lymphomas with irreversible resistance to Fas-induced apoptosis.

Cancer Res. 59:696-703(1999)

PubMed=10739008; DOI=10.1016/S0145-2126(99)00182-4

Inoue K., Kohno T., Takakura S., Hayashi Y., Mizoguchi H., Yokota J.

Frequent microsatellite instability and BAX mutations in T cell acute lymphoblastic leukemia cell lines.

Leuk. Res. 24:255-262(2000)

PubMed=11021758; DOI=10.1038/sj.leu.2401891

Majka M., Rozmyslowicz T., Honczarenko M.J., Ratajczak J., Wasik M.A., Gaulton G.N., Ratajczak M.Z.

Biological significance of the expression of HIV-related chemokine coreceptors (CCR5 and CXCR4) and their ligands by human hematopoietic cell lines.

Leukemia 14:1821-1832(2000)

PubMed=11226526; DOI=10.1016/S0145-2126(00)00121-1

Inoue K., Kohno T., Takakura S., Hayashi Y., Mizoguchi H., Yokota J.

Corrigendum to: Frequent microsatellite instability and BAX mutations in T cell acute lymphoblastic leukemia cell lines Leukemia Research 24 (2000), 255-262.

Leuk. Res. 25:275-278(2001)

PubMed=12145705; DOI=10.1038/sj.leu.2402519

Langerak A.W., Moreau E.J., van Gastel-Mol E.J., van der Burg M., van Dongen J.J.M.

Detection of clonal EBV episomes in lymphoproliferations as a diagnostic tool.

Leukemia 16:1572-1573(2002)

PubMed=12967475; DOI=10.1111/j.1349-7006.2003.tb01518.x; PMCID=PMC11160262

Maesako Y., Uchiyama T., Ohno H.

Comparison of gene expression profiles of lymphoma cell lines from transformed follicular lymphoma, Burkitt's lymphoma and de novo diffuse large B-cell lymphoma.

Cancer Sci. 94:774-781(2003)

PubMed=14504097; DOI=10.1182/blood-2003-02-0418

Taketani T., Taki T., Sugita K., Furuichi Y., Ishii E., Hanada R., Tsuchida M., Sugita K., Ida K., Hayashi Y.

FLT3 mutations in the activation loop of tyrosine kinase domain are frequently found in infant ALL with MLL rearrangements and pediatric ALL with hyperdiploidy.

Blood 103:1085-1088(2004)

PubMed=15028022; DOI=10.1111/j.1440-1827.2004.01612.x

Kamimura K., Hojo H., Abe M.

Characterization of expression of protein kinase C isozymes in human B-cell lymphoma: relationship between its expression and prognosis.

Pathol. Int. 54:224-230(2004)

PubMed=19358282; DOI=10.1002/ijc.24351

Inagaki A., Ishida T., Yano H., Ishii T., Kusumoto S., Ito A., Ri M., Mori F., Ding J.-M., Komatsu H., Iida S., Ueda R.

Expression of the ULBP ligands for NKG2D by B-NHL cells plays an important role in determining their susceptibility to rituximab-induced ADCC.

Int. J. Cancer 125:212-221(2009)

PubMed=20164919; DOI=10.1038/nature08768; PMCID=PMC3145113

Bignell G.R., Greenman C.D., Davies H.R., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Signatures of mutation and selection in the cancer genome.

Nature 463:893-898(2010)

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458; PMCID=PMC2881662

Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Cancer Res. 70:2158-2164(2010)

PubMed=20454443; DOI=10.1155/2010/904767; PMCID=PMC2861168

Uphoff C.C., Denkmann S.A., Steube K.G., Drexler H.G.

Detection of EBV, HBV, HCV, HIV-1, HTLV-I and -II, and SMRV in human and other primate cell lines.

J. Biomed. Biotechnol. 2010:904767.1-904767.23(2010)

PubMed=22460905; DOI=10.1038/nature11003; PMCID=PMC3320027

Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Nature 483:603-607(2012)

PubMed=22885699; DOI=10.1038/nature11378; PMCID=PMC3609867

Schmitz R., Young R.M., Ceribelli M., Jhavar S., Xiao W.-M., Zhang M.-L., Wright G., Shaffer A.L. 3rd, Hodson D.J., Buras E., Liu X.-L., Powell J.I., Yang Y.-D., Xu W.-H., Zhao H., Kohlhammer H., Rosenwald A., Kluin P.M., Muller-Hermelink H.-K., Ott G., Gascoyne R.D., Connors J.M., Rimsza L.M., Campo E., Jaffe E.S., Delabie J., Smeland E.B., Ogwang M.D., Reynolds S.J., Fisher R.I., Braziel R.M., Tubbs R.R., Cook J.R., Weisenburger D.D., Chan W.-C., Pittaluga S., Wilson W., Waldmann T.A., Rowe M., Mbulaiteye S.M., Rickinson A.B., Staudt L.M.

Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics.

Nature 490:116-120(2012)

PubMed=24590883; DOI=10.1002/gcc.22161

Murga Penas E.-M., Schilling G., Behrmann P., Klokow M., Vettorazzi E., Bokemeyer C., Dierlamm J.

Comprehensive cytogenetic and molecular cytogenetic analysis of 44 Burkitt lymphoma cell lines: secondary chromosomal changes characterization, karyotypic evolution, and comparison with primary samples.

Genes Chromosomes Cancer 53:497-515(2014)

PubMed=25960936; DOI=10.4161/21624011.2014.954893; PMCID=PMC4355981

Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.

A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines.

OncoImmunology 3:e954893.1-e954893.12(2014)

PubMed=25355872; DOI=10.1128/JVI.02570-14; PMCID=PMC4301145

Cao S.-B., Strong M.J., Wang X., Moss W.N., Concha M., Lin Z., O'Grady T., Baddoo M., Fewell C., Renne R., Flemington E.K.

High-throughput RNA sequencing-based virome analysis of 50 lymphoma cell lines from the Cancer Cell Line Encyclopedia project.

J. Virol. 89:713-729(2015)

PubMed=25485619; DOI=10.1038/nbt.3080

Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S., Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.-M.

A comprehensive transcriptional portrait of human cancer cell lines.

Nat. Biotechnol. 33:306-312(2015)

PubMed=25877200; DOI=10.1038/nature14397

Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M., Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S., Neve R.M.

A resource for cell line authentication, annotation and quality control.

Nature 520:307-311(2015)

PubMed=26589293; DOI=10.1186/s13073-015-0240-5; PMCID=PMC4653878

Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P., Loewer M., Sahin U., Castle J.C.

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Genome Med. 7:118.1-118.7(2015)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017; PMCID=PMC4967469

Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Miroo T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

A landscape of pharmacogenomic interactions in cancer.

Cell 166:740-754(2016)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005; PMCID=PMC5501076

Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P., Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B., Liang H.

Characterization of human cancer cell lines by reverse-phase protein arrays.

Cancer Cell 31:225-239(2017)

PubMed=29892436; DOI=10.1098/rsos.172472; PMCID=PMC5990783

Shioda S., Kasai F., Watanabe K., Kawakami K., Ohtani A., Iemura M., Ozawa M., Arakawa A., Hirayama N., Kawaguchi E., Tano T., Miyata S., Satoh M., Shimizu N., Kohara A.

Screening for 15 pathogenic viruses in human cell lines registered at the JCRB Cell Bank: characterization of in vitro human cells by viral infection.

R. Soc. Open Sci. 5:172472-172472(2018)

PubMed=30285677; DOI=10.1186/s12885-018-4840-5; PMCID=PMC6167786

Tan K.-T., Ding L.-W., Sun Q.-Y., Lao Z.-T., Chien W., Ren X., Xiao J.-F., Loh X.-Y., Xu L., Lill M., Mayakonda A., Lin D.-C., Yang H.H., Koeffler H.P.

Profiling the B/T cell receptor repertoire of lymphocyte derived cell lines.

BMC Cancer 18:940.1-940.13(2018)

PubMed=30629668; DOI=10.1371/journal.pone.0210404; PMCID=PMC6328144

Uphoff C.C., Pommerenke C., Denkmann S.A., Drexler H.G.

Screening human cell lines for viral infections applying RNA-Seq data analysis.

PLoS ONE 14:E0210404-E0210404(2019)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747; PMCID=PMC6445675

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Cancer Res. 79:1263-1273(2019)"